 complications were observed in patients receiving coumarin as in those receiving ASA.
Despite the ﬁndings of the BOA trial, most vascular
surgeons in the United States choose not to routinely anticoagulate patients undergoing lower extremity vein bypass.
However, anticoagulant therapy may be beneﬁcial in speciﬁc circumstances where conditions are less than optimal.
In a small trial by Sarac et al,238 56 patients undergoing
high-risk vein